Cyclopamine

Catalog No.S1146 Synonyms: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 370 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

    (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

  • (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

    For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Targets
Smoothened [1]
(TM3Hh12 cells)
46 nM
In vitro

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 MoXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\pemlEPTB;NT64OlY3KM7:TR?= Ml31V2FPT0WU
DOHH-2 M1jDbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonTTWM2OD17LkO1Olg6KM7:TR?= MmXGV2FPT0WU
no-10 NGjWRotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LZbGlEPTB;OT65NFM6KM7:TR?= NGr2cYtUSU6JRWK=
LS-513 MmrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D6ZWlEPTB;MUGuN|U1PyEQvF2= MlXHV2FPT0WU
ALL-PO M3;2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rDOGlEPTB;MUGuO|c{PCEQvF2= NWrDbJRJW0GQR1XS
8-MG-BA MlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTF|LkGxNlMh|ryP MXjTRW5ITVJ?
RPMI-8402 NEXvZZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTGTWM2OD1zNT64OVM4KM7:TR?= NEHTOI5USU6JRWK=
EoL-1-cell NXXlT4xHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTF6LkW5OFgh|ryP NFf5VXZUSU6JRWK=
NALM-6 M2[5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33PbmlEPTB;MUmuNFE3PyEQvF2= NHq2bHpUSU6JRWK=
DEL MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJyLkG0O|Eh|ryP NEf5emxUSU6JRWK=
SR MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHH2UlJKSzVyPUKzMlY4OTVizszN NVvMfmJnW0GQR1XS
697 NHrGUFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nzUGlEPTB;Mk[uOlE2PSEQvF2= NYjCV5FQW0GQR1XS
COLO-829 M3jZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzQeHZKSzVyPUK2Mlg1QDNizszN Mon2V2FPT0WU
EVSA-T NXzQfHl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfrTWM2OD1{Nz61OVYyKM7:TR?= MmLoV2FPT0WU
ATN-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LtSGlEPTB;M{GuNlMzQSEQvF2= MkK4V2FPT0WU
L-363 M2r2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTNzLke0OlEh|ryP NGXoOIlUSU6JRWK=
LAMA-84 NUXaWVkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHpTWM2OD1|Mj61NlEyKM7:TR?= NFX4VJpUSU6JRWK=
NOS-1 M{WyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4f0cmlEPTB;M{SuNlk2PiEQvF2= NEXoUJJUSU6JRWK=
BB30-HNC M1;QbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7vTWM2OD1|ND6zN|A3KM7:TR?= MVrTRW5ITVJ?
BC-1 NYTuSZViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIr2Om5KSzVyPUO3Mlk4PDZizszN NYTWeZdPW0GQR1XS
IST-SL2 NIixWW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTN6LkKyOEDPxE1? NXLZNY5qW0GQR1XS
D-392MG NUDTTpplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;WTWM2OD12MD6yNlE2KM7:TR?= M3XpV3NCVkeHUh?=
no-11 M{XBNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\PTWM2OD12MD61OVIyKM7:TR?= NV;p[G9vW0GQR1XS
LC4-1 NIOxbZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\uTWM2OD12MD64O|E3KM7:TR?= NWLZTZBFW0GQR1XS
A388 NXvHfGhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XmU2lEPTB;NEKuOVg1QCEQvF2= MUTTRW5ITVJ?
NTERA-S-cl-D1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTR{LkewO|Qh|ryP MkXtV2FPT0WU
CESS MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTR2LkKyN|Ih|ryP NWLGNYtqW0GQR1XS
RS4-11 MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TMUWlEPTB;NEmuNFk{QCEQvF2= MVnTRW5ITVJ?
MS-1 M1[5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2L2V2lEPTB;NUCuPVM2OSEQvF2= M2PxXHNCVkeHUh?=
CTV-1 NVL2bI5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTacHJpUUN3ME21NU4xPzRizszN NYOzepQxW0GQR1XS
D-502MG NYrQVo1XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkG3TWM2OD13MT62NlcyKM7:TR?= MnjWV2FPT0WU
ML-2 NHf4SJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlT0TWM2OD13Mj65NVk2KM7:TR?= Mki1V2FPT0WU
SK-NEP-1 NH\JOZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXu0RnNMUUN3ME21N{4{QTJ|IN88US=> MXTTRW5ITVJ?
LOXIMVI NHTK[JpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPjd3F{UUN3ME21N{42QDh2IN88US=> NF\PcGdUSU6JRWK=
DJM-1 M2S3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jkWGlEPTB;NU[uN|M6OSEQvF2= MnPYV2FPT0WU
GI-1 NWPUdGZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTV4Lk[xOFkh|ryP M4XIZXNCVkeHUh?=
IST-MES1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPqZVljUUN3ME22NE42PDl|IN88US=> NEL1bnhUSU6JRWK=
MV-4-11 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTZyLk[1N|gh|ryP NHqwS3FUSU6JRWK=
OVCAR-4 M2rQVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTZ|LkW2OVch|ryP NV\3WHg6W0GQR1XS
KE-37 NVrrXFBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37mOGlEPTB;Nk[uNlY3QCEQvF2= MnyzV2FPT0WU
D-542MG MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37F[2lEPTB;NkiuOFE{PSEQvF2= MoH4V2FPT0WU
MHH-PREB-1 NF\kcodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTqeXRSUUN3ME23Nk45PDRzIN88US=> MWPTRW5ITVJ?
MRK-nu-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\HTWM2OD15Mz60O|A2KM7:TR?= MXLTRW5ITVJ?
D-247MG M{HyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLpTWM2OD15Mz61OFQzKM7:TR?= M1jrXXNCVkeHUh?=
OCI-AML2 NXXjT5BCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\iSnBmUUN3ME23Ok46OzZ7IN88US=> MV3TRW5ITVJ?
LP-1 NFHKSI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\hN3dKSzVyPUiyMlg4OzFizszN M2T2XnNCVkeHUh?=
HCC1599 NHT3[IRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnH[nQyUUN3ME24OE4zQDN5IN88US=> NVyxfpF2W0GQR1XS
KARPAS-45 NG\pOHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2S1RWlEPTB;OESuOlk6OiEQvF2= NGTXV4NUSU6JRWK=
BE-13 M3\0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXXTWM2OD17OT6wOFc4KM7:TR?= NWX0VVd7W0GQR1XS
GCIY NYTnbFNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIraRWZKSzVyPUm5MlA6PTRizszN M3nScHNCVkeHUh?=
BV-173 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3Z[WJVUUN3ME2xNFAvOzJ3IN88US=> NX\Te41JW0GQR1XS
LB2518-MEL M1zu[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvEVnB4UUN3ME2xNFAvPzh7IN88US=> NV;lXJZzW0GQR1XS
KS-1 NWDDUVZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Lpb2lEPTB;MUCxMlY{QSEQvF2= NVTDSJp6W0GQR1XS
MOLT-16 NVqxb3p4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTWT3d6UUN3ME2xNFQvQTh4IN88US=> MmW0V2FPT0WU
NCI-H1770 M2rub2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\Pe2lEPTB;MUC4Mlc5PCEQvF2= Moj6V2FPT0WU
NCI-H82 NFXrbmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLYTWM2OD1zMUCuPVc3KM7:TR?= NEK4dIlUSU6JRWK=
NCCIT MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm[zTWM2OD1zMUKuOVI6KM7:TR?= MkPDV2FPT0WU
KALS-1 Mny1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojxTWM2OD1zMUWuPVQyKM7:TR?= M4r0S3NCVkeHUh?=
LB2241-RCC M1nXXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTFzNj62O|kh|ryP NEfBSotUSU6JRWK=
HH MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYq1bmVrUUN3ME2xNVcvOzl3IN88US=> MkL2V2FPT0WU
HD-MY-Z MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrze41JUUN3ME2xNVgvPDh6IN88US=> NUTvVJdWW0GQR1XS
EB-3 MoPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnH0TWM2OD1zMkOuNFk1KM7:TR?= M{HNbnNCVkeHUh?=
BL-70 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHEcG5MUUN3ME2xNlMvOTJ5IN88US=> NF64cmlUSU6JRWK=
K-562 NF\a[pZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTF{Nj6yOFUh|ryP M{XoSXNCVkeHUh?=
HT-144 M2nXbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2CyO2lEPTB;MUOzMlE3PCEQvF2= M3HyVnNCVkeHUh?=
PF-382 MoD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjNS4xKSzVyPUGzOE4{PjFizszN NGXnRW5USU6JRWK=
RPMI-8226 M1HJeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTF|NT6wOFUh|ryP MlHuV2FPT0WU
NCI-H1355 NGrubY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLvTWM2OD1zM{WuOVg4KM7:TR?= Ml:1V2FPT0WU
LXF-289 MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4iwVGlEPTB;MUO5Mlc5OSEQvF2= NXjPXHM1W0GQR1XS
NCI-H69 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDoRY9KSzVyPUG0Nk46OzJizszN NW\4bmFGW0GQR1XS
SK-MEL-1 NVO3d4JGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzhTWM2OD1zNEeuNVMh|ryP M4GyUnNCVkeHUh?=
KARPAS-299 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLTTWM2OD1zNEmuNVIh|ryP NUKzPGdxW0GQR1XS
GB-1 M4CzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTF2OT6zNlIh|ryP NXewXmo5W0GQR1XS
CMK NUnsR5lFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13yc2lEPTB;MUS5MlUyPSEQvF2= NWHQcodYW0GQR1XS
MPP-89 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknaTWM2OD1zNU[uNFM2KM7:TR?= M4HqXHNCVkeHUh?=
KU812 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrUXZNKSzVyPUG2NU46ODJizszN NH;ud3dUSU6JRWK=
REH M1rZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTHToJNUUN3ME2xOlIvOTJ3IN88US=> NVr6VGNWW0GQR1XS
NEC8 NXPvR5BJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPOO3VKSzVyPUG2OU4xOjZizszN MVPTRW5ITVJ?
KP-N-YS M37XWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmf0TWM2OD1zNkiuN|k2KM7:TR?= NWjJW4FDW0GQR1XS
Ramos-2G6-4C10 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTF4OT65NVUh|ryP NV[0dFM5W0GQR1XS
Becker NEGxd5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjlTWM2OD1zN{SuNVgh|ryP NG\EdFdUSU6JRWK=
LB647-SCLC MoG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2CwU2lEPTB;MUe1Mlg1PSEQvF2= NIrsNGRUSU6JRWK=
LU-139 NH;KT5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrVfI1uUUN3ME2xO|gvODF7IN88US=> MXLTRW5ITVJ?
QIMR-WIL M4D6e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLSNlZKSzVyPUG3PU43PDZizszN NGi1bIVUSU6JRWK=
NCI-H1395 M1Wycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\Ib|lKSzVyPUG3PU46QTZizszN MWHTRW5ITVJ?
NOMO-1 NWfMZYt1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13jN2lEPTB;MUiyMlg2KM7:TR?= M4rh[HNCVkeHUh?=
GI-ME-N NUj1RVZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV72dXpRUUN3ME2xPFcvQTZ7IN88US=> MWrTRW5ITVJ?
KMS-12-PE MmHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Xzd2lEPTB;MUi5MlI4OyEQvF2= MVvTRW5ITVJ?
Daudi MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nWPGlEPTB;MUmxMlEzQCEQvF2= NHX2UllUSU6JRWK=
LB996-RCC MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrySWp5UUN3ME2xPVEvPjl7IN88US=> NV\vWHJ1W0GQR1XS
NCI-H2107 NIrQO2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFGwU|ZKSzVyPUG5N{44OzlizszN M{HwPHNCVkeHUh?=
SK-PN-DW NH:xeWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTF7ND63NVkh|ryP MX;TRW5ITVJ?
MC-CAR NH7TeXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLpTWM2OD1{MEKuNlU{KM7:TR?= MlLUV2FPT0WU
SNB75 NHLWO45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPHNXZtUUN3ME2yNlEvQTRizszN NXL5fINFW0GQR1XS
ES4 NWLGd49LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rSfmlEPTB;MkKzMlc5OyEQvF2= NXnUTIVPW0GQR1XS
KARPAS-422 NVTDeXQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjQTWM2OD1{MkiuN|UzKM7:TR?= NGLqfHpUSU6JRWK=
NCI-H1648 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPMTWM2OD1{MkmuOFg6KM7:TR?= MoP0V2FPT0WU
ES6 NX72WIkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfaTWM2OD1{M{muOFMh|ryP NGLyclJUSU6JRWK=
KNS-81-FD M4\6UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\FW5hRUUN3ME2yOFEvOTl5IN88US=> NF7BWo1USU6JRWK=
JAR MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJ3Nj6yNlUh|ryP NFuwbIJUSU6JRWK=
NB1 M3LsUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIf0XIdKSzVyPUK2NE42OTZizszN MX7TRW5ITVJ?
D-336MG M1;MV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPFcoZKSzVyPUK2NE43QThizszN M1W4T3NCVkeHUh?=
BC-3 M4m0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jGe2lEPTB;Mk[1MlE4QCEQvF2= M{PyfHNCVkeHUh?=
HCC2218 NV7mUXlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DLU2lEPTB;Mk[2MlQyPSEQvF2= NV7DdINNW0GQR1XS
TE-9 NVPvV5ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTJ4Nj62Nlch|ryP M1LafnNCVkeHUh?=
LB1047-RCC NYjTO4RYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTJ4Nj63OVMh|ryP NYXTSI9RW0GQR1XS
CTB-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrpTWM2OD1{NkmuPVc{KM7:TR?= MVvTRW5ITVJ?
NB7 NIfhNnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJ5MTFOwG0> MkP2V2FPT0WU
ST486 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;iR2lEPTB;Mke3MlQyOiEQvF2= NVK2ZXdvW0GQR1XS
HCC1187 M4C4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTJ6Mj64NVEh|ryP NUTu[2NmW0GQR1XS
NCI-SNU-16 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTJ6ND6yOFgh|ryP NGHtXmxUSU6JRWK=
COR-L279 M1TCXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;ENpVKSzVyPUK5NU42QDRizszN MmDxV2FPT0WU
ES8 M4\NPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTZZXJ{UUN3ME2yPVQvOTh{IN88US=> NHu5fYlUSU6JRWK=
U-698-M MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTXbXVKSzVyPUK5PE4zPDNizszN M3XNe3NCVkeHUh?=
HEL MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zoV2lEPTB;M{C5MlE1QSEQvF2= NHLNSnBUSU6JRWK=
KINGS-1 MmHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTNzMD62O|Qh|ryP NGfrU2VUSU6JRWK=
KY821 Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zkfGlEPTB;M{O2MlU6PSEQvF2= NXq5UIk1W0GQR1XS
MZ1-PC NInnZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvLOItKSzVyPUO0OU43OThizszN NIexUVdUSU6JRWK=
LS-411N NHL4V5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzyeFVKSzVyPUO1OE43PiEQvF2= MnPaV2FPT0WU
SIG-M5 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTN3OT63PFIh|ryP M3TXUnNCVkeHUh?=
HT NXzCSldUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGL5VYpKSzVyPUO2O{44OTFizszN M3fCR3NCVkeHUh?=
HC-1 NGjocGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTN4Nz63PFch|ryP MlraV2FPT0WU
NCI-H1694 M3nDWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTN5Mj65N|Qh|ryP M1H6N3NCVkeHUh?=
BB65-RCC NVG0R2c1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLyOVFKSzVyPUO3Ok4zPDVizszN M2r0Z3NCVkeHUh?=
HAL-01 MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HFN2lEPTB;M{e5Mlg{QCEQvF2= NIPSVW1USU6JRWK=
ARH-77 NEOzenlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[0fGVUUUN3ME2zPVQvODB6IN88US=> NXrCdpUxW0GQR1XS
MZ7-mel MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3TUJNpUUN3ME2zPVcvOjN|IN88US=> NYXnO5hwW0GQR1XS
SIMA NHfMOFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7od|NWUUN3ME20NFMvQTN|IN88US=> M3fvdHNCVkeHUh?=
DG-75 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;wR|lzUUN3ME20NVUvPjl6IN88US=> MkHDV2FPT0WU
HUTU-80 NX3BcJZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTRzOT6xPFUh|ryP NWHEOXVkW0GQR1XS
KNS-42 M3nDVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7iTWM2OD12MkWuPFE2KM7:TR?= NUTvToxwW0GQR1XS
SH-4 M1:zd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfsflFiUUN3ME20NlcvPTZ3IN88US=> NGXlTG1USU6JRWK=
L-540 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPVTWM2OD12M{GuNFMyKM7:TR?= NEXy[29USU6JRWK=
NB10 NU\Ie2hFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV61dmxOUUN3ME20OFEvOjN2IN88US=> MoPCV2FPT0WU
ES1 M{Ln[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTR3Mj63OVMh|ryP NF\GNXRUSU6JRWK=
KMOE-2 NVvZPYZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTR3Nj63NVEh|ryP NUOzOWFVW0GQR1XS
MC116 Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4P2SmlEPTB;NEW4MlEyPiEQvF2= MX7TRW5ITVJ?
RCC10RGB Mn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTlNGN6UUN3ME20OlAvODB3IN88US=> MlL5V2FPT0WU
RL95-2 MoPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{X6RWlEPTB;NE[wMlI{PyEQvF2= Mlz1V2FPT0WU
Raji MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDlTWM2OD12NkiuNVQ{KM7:TR?= NVTpXXR3W0GQR1XS
CAS-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlW5TWM2OD12N{KuNFc{KM7:TR?= MoLmV2FPT0WU
Calu-6 NFPaZndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTR5NT6yOlUh|ryP NF;NU25USU6JRWK=
KG-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1j4fWlEPTB;NEe4MlQ1KM7:TR?= NXPM[YwzW0GQR1XS
LB771-HNC NV33UIVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTR6Mj6yN|Ih|ryP MonpV2FPT0WU
ACN M{nhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnYc41OUUN3ME20PVMvPTl7IN88US=> Mk\iV2FPT0WU
KM12 NXXzZVNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HnWGlEPTB;NEm2MlU5QSEQvF2= MkHVV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]

Protocol

Kinase Assay:[1]
+ Expand

Hedgehog cell assay:

This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
Cell Research:[2]
+ Expand
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
  • Concentrations: Dissolved in DMSO, final concentration 3 μM
  • Incubation Time: 4 days
  • Method: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 50 mg/kg/day
  • Administration: Subcutaneous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble
In vivo Add solvents to the product individually and in order:
10% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
1mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 411.62
Formula

C27H41NO2

CAS No. 4449-51-8
Storage powder
Synonyms 11-deoxojervine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo use in mice?

  • Answer:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Related Hedgehog/Smoothened Products

Tags: buy Cyclopamine | Cyclopamine supplier | purchase Cyclopamine | Cyclopamine cost | Cyclopamine manufacturer | order Cyclopamine | Cyclopamine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID